Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Treatment With Simvastatin and Rifaximin Restores the Plasma Metabolomic Profile in Patients With Decompensated Cirrhosis

  • Pose, Elisa|||0000-0002-0224-7686
  • Solà, Elsa|||0000-0001-6897-2760
  • Lozano, Juan José
  • Juanola, Adrià|||0000-0003-4832-5130
  • Sidorova, Julia
  • Zaccherini, Giacomo|||0000-0002-3219-6963
  • de Wit, Koos|||0000-0001-8472-8549
  • Uschner, Frank
  • Tonon, Marta
  • Kazankov, Konstantin
  • Jiménez, Cesar|||0000-0003-2455-2048
  • Campion, Daniela
  • Napoleone, Laura
  • Ma, Ann T.|||0000-0002-9059-111X
  • Carol, Marta
  • Morales Ruiz, Manuel|||0000-0002-9074-2272
  • Alessandria, Carlo|||0000-0001-5468-694X
  • Beuers, Ulrich
  • Caraceni, Paolo|||0000-0002-1439-056X
  • Francoz, Claire|||0000-0001-7391-8507
  • Durand, François
  • Mookerjee, Rajeshwar P.
  • Trebicka, Jonel|||0000-0002-7028-3881
  • Vargas Blasco, Víctor|||0000-0002-7190-6948
  • Piano, Salvatore|||0000-0002-9356-5830
  • Watson, Hugh|||0000-0002-6931-3158
  • Abraldes, Juan G.|||0000-0003-3421-937X
  • Kamath, P.S.|||0000-0002-7888-1165
  • Davis, Mark M.
  • Ginès, Pere|||0000-0003-4657-4504
Patients with decompensated cirrhosis, particularly those with acute-on-chronic liver failure (ACLF), show profound alterations in plasma metabolomics. The aim of this study was to investigate the effect of treatment with simvastatin and rifaximin on plasma metabolites of patients with decompensated cirrhosis, specifically on compounds characteristic of the ACLF plasma metabolomic profile. Two cohorts of patients were investigated. The first was a descriptive cohort of patients with decompensated cirrhosis (n = 42), with and without ACLF. The second was an intervention cohort from the LIVERHOPE-SAFETY randomized, double-blind, placebo-controlled trial treated with simvastatin 20 mg/day plus rifaximin 1,200 mg/day (n = 12) or matching placebo (n = 13) for 3 months. Plasma samples were analyzed using ultrahigh performance liquid chromatography-tandem mass spectroscopy for plasma metabolomics characterization. ACLF was characterized by intense proteolysis and lipid alterations, specifically in pathways associated with inflammation and mitochondrial dysfunction, such as the tryptophan-kynurenine and carnitine beta-oxidation pathways. An ACLF-specific signature was identified. Treatment with simvastatin and rifaximin was associated with changes in 161 of 985 metabolites in comparison to treatment with placebo. A remarkable reduction in levels of metabolites from the tryptophan-kynurenine and carnitine pathways was found. Notably, 18 of the 32 metabolites of the ACLF signature were affected by the treatment. Conclusion: Treatment with simvastatin and rifaximin modulates some of the pathways that appear to be key in ACLF development. This study unveils some of the mechanisms involved in the effects of treatment with simvastatin and rifaximin in decompensated cirrhosis and sets the stage for the use of metabolomics to investigate new targeted therapies in cirrhosis to prevent ACLF development.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The Use of Rifaximin in Patients With Cirrhosis

  • Caraceni, Paolo|||0000-0002-1439-056X
  • Vargas Blasco, Víctor|||0000-0002-7190-6948
  • Solà, Elsa|||0000-0001-6897-2760
  • Alessandria, Carlo|||0000-0001-5468-694X
  • de Wit, Koos|||0000-0001-8472-8549
  • Trebicka, Jonel|||0000-0002-7028-3881
  • Angeli, Paolo|||0000-0002-1913-0716
  • Mookerjee, Rajeshwar P.
  • Durand, François
  • Pose, Elisa|||0000-0002-0224-7686
  • Krag, Aleksander|||0000-0002-9598-4932
  • Bajaj, Jasmohan S.|||0000-0003-4928-3681
  • Beuers, Ulrich
  • Ginès, Pere|||0000-0003-4657-4504
Rifaximin is an oral nonsystemic antibiotic with minimal gastrointestinal absorption and broad-spectrum antibacterial activity covering both gram-positive and gram-negative organisms. Rifaximin is currently used worldwide in patients with cirrhosis for preventing recurrent HE because its efficacy and safety have been proven by large randomized clinical trials. In the last decade, experimental and clinical evidence suggest that rifaximin could have other beneficial effects on the course of cirrhosis by modulating the gut microbiome and affecting the gut-liver axis, which in turn can interfere with major events of the pathophysiological cascade underlying decompensated cirrhosis, such as systemic inflammatory syndrome, portal hypertension, and bacterial infections. However, the use of rifaximin for prevention or treatment of other complications, including spontaneous bacterial peritonitis or other bacterial infections, is not accepted because evidence by clinical trials is still very weak. The present review deals in the first part with the potential impact of rifaximin on pathogenic mechanisms in liver diseases, whereas in the second part, its clinical effects are critically discussed. It clearly emerges that, because of its potential activity on multiple pathogenic events, the efficacy of rifaximin in the prevention or management of complications other than HE deserves to be investigated extensively. The results of double-blinded, adequately powered randomized clinical trials assessing the effect of rifaximin, alone or in combination with other drugs, on hard clinical endpoints, such as decompensation of cirrhosis, acute-on-chronic liver failure, and mortality, are therefore eagerly awaited.